Eli Lilly Partners with Hims & Hers for Direct-to-Consumer Weight Loss Drug Sales; Hims Surges Over 7% Premarket
nashnova research
Eli Lilly struck a deal to sell its weight-loss drugs Zepbound and Foundayo directly on the Hims & Hers platform, sending Hims shares up over 7% pre-market — a signal that the GLP-1 battle is shifting from who has the drug to who owns the last mile to the patient.
What does this deal actually change?
Previously, Hims & Hers users who wanted Lilly's weight-loss drugs had to leave the platform and complete the purchase on LillyDirect — Lilly's own cash-pay site. Every extra step costs conversions.
This means → the deal isn't about a new drug launch. It's about removing purchase friction — one app, one checkout.
Lilly's U.S. president Ilya Yuffa stated the logic plainly: any friction in the buying process raises the probability a patient abandons the purchase.
How is it priced — and how does it compare to Novo?
Foundayo (Lilly's oral weight-loss pill) starts at $149/month out-of-pocket; Zepbound (injectable) starts at $299/month — matching LillyDirect's existing prices.
Novo Nordisk's Wegovy oral pill also starts at $149/month, but the Wegovy injection pen starts at $199/month — $100 cheaper than Zepbound.
In plain terms = on oral pills, they're even. On injectables, Lilly is pricier — it's competing on convenience, not on cost.
Why is Novo Nordisk the unavoidable benchmark?
Novo Nordisk began selling Wegovy and Ozempic on Hims & Hers back in March — months ahead of Lilly.
This means → Lilly's deal is essentially catching up to a rival's channel position, not leapfrogging it.
Context: the two sides previously clashed in court over compounded copies. Hims & Hers had been selling knockoff versions of Lilly's drugs — a key condition of this deal is that Hims & Hers commits to stop selling any compounded or counterfeit versions of Lilly's obesity drugs.
Is Foundayo struggling — and can this deal help?
Bloomberg reported that Foundayo's quarterly sales through October missed market expectations. Lilly recently ramped up marketing, including a campaign featuring Martha Stewart.
This reflects an oral weight-loss market still climbing its adoption curve. Hims & Hers' user base could give Foundayo a new path to reach patients.
Roughly 30%-40% of obesity patients access drugs through telehealth channels, and 40%-45% of Zepbound sales come from cash-pay users — precisely the demographic Hims & Hers serves.
What does this mean for each company?
Lilly raised its full-year revenue guidance by $5 billion last week, citing strong injectable demand. Its market cap sits at roughly $1.2 trillion, leading the global obesity-drug market.
Hims & Hers CEO Andrew Dudum said the two companies expect to collaborate for years on Lilly's pipeline drugs, including the closely watched next-generation candidate retatrutide.
This means → for Hims & Hers, this isn't just adding a supplier — it's locking in distribution rights to the next generation of the drug pipeline. The 7% pre-market jump prices in that long-term optionality, not just today's shelf space.
市场有风险，内容仅供研究参考，不构成投资建议。